Revenue: As of FY2026 Q1, the actual value is USD 24.27 M, beating the estimate of USD 22.4 M.

EPS: As of FY2026 Q1, the actual value is USD 0.05, missing the estimate of USD 0.09.

EBIT: As of FY2026 Q1, the actual value is USD 3.55 M.

Eton Pharmaceuticals, Inc. operates as a single reportable segment focused on rare disease treatments.

Segment Revenue

Total net revenues for the three months ended March 31, 2026, were $24,266 thousand, increasing from $17,282 thousand for the same period in 2025. Product sales and royalties, net, increased due to higher sales of INCRELEX®, GALZIN®, ALKINDI SPRINKLE®, and Carglumic Acid, along with the addition of KHINDIVI™ sales. Licensing revenue was $0 for the three months ended March 31, 2026, compared to $3,286 thousand for the same period in 2025. The 2025 licensing revenue included $1,786 thousand from out-licensing INCRELEX® rights outside the U.S. and $1,500 thousand from a development milestone related to the divestiture of DS-200.

Operational Metrics

Gross profit was $14,735 thousand for the three months ended March 31, 2026, up from $9,861 thousand for the same period in 2025. Research and Development (R&D) expenses increased to $1,875 thousand for the three months ended March 31, 2026, from $1,161 thousand for the same period in 2025, mainly due to higher clinical study expenses for KHINDIVI™ label expansion and ET-700 project development activities. General and Administrative (G&A) expenses rose to $10,446 thousand for the three months ended March 31, 2026, from $9,170 thousand for the same period in 2025, primarily due to higher FDA fees and increased employee-related costs. The company reported a net income of $1,554 thousand for the three months ended March 31, 2026, compared to a net loss of -$1,572 thousand for the same period in 2025.

Cash Flow

Net cash from operating activities was $7,405 thousand for the three months ended March 31, 2026, an increase from $2,090 thousand for the same period in 2025, driven mainly by higher cash collections from product sales and lower inventory purchases. Net cash used in investing activities was -$15,075 thousand for the three months ended March 31, 2026, compared to $0 for the same period in 2025. This was primarily due to a $14,000 thousand payment for HEMANGEOL® U.S. commercial rights and a $1,000 thousand upfront payment for an ultra-rare disease product candidate license. Net cash from financing activities was $1,389 thousand for the three months ended March 31, 2026, up from $394 thousand for the same period in 2025, attributed to increased proceeds from stock option exercises. The change in cash and cash equivalents was -$6,281 thousand for the three months ended March 31, 2026, compared to $2,484 thousand for the same period in 2025.

Unique Metrics (Non-GAAP Financial Measures)

EBITDA was $3,841 thousand for the three months ended March 31, 2026, versus $678 thousand for the same period in 2025. Adjusted EBITDA was $5,709 thousand for the three months ended March 31, 2026, compared to $3,675 thousand for the same period in 2025. Non-GAAP net income was $4,482 thousand for the three months ended March 31, 2026, up from $2,395 thousand for the same period in 2025. Non-GAAP income per share (diluted) was $0.14 for the three months ended March 31, 2026, compared to $0.07 for the same period in 2025.

Future Outlook and Strategy

The Management’s Discussion and Analysis section does not contain explicit forward-looking statements or guidance regarding future financial performance, growth targets, or strategic plans beyond general business operations and product development efforts.